Tirabrutinib vs standard therapy for relapsed PCNSL
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests a new oral targeted drug called tirabrutinib against a standard treatment combination (rituximab plus temozolomide) for people whose primary central nervous system lymphoma has come back or not responded to prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called B-cell primary central nervous system lymphoma (PCNSL), which started in your brain or spinal cord.
- Your lymphoma came back or did not respond after at least one round of high-dose methotrexate therapy.
- You have at least one brain tumor that can be measured on an MRI scan, at least 1 cm in size.
- You are able to take care of most daily activities (ECOG performance status 0 to 2).
- You are able to swallow pills.
- You have not taken a Bruton's tyrosine kinase inhibitor (like ibrutinib or zanubrutinib) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the drug tirabrutinib (a pill) can help keep primary CNS lymphoma from coming back after successful initial chemotherapy. It compares the drug to a placebo (a dummy pill).
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a combination of three drugs (high-dose methotrexate, thiotepa, and zanubrutinib) for people who have just been diagnosed with primary central nervous system lymphoma (PCNSL). The goal is to see if this three-drug cocktail works better than standard treatments.
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
Hear when a new Relapsed/Refractory Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.